The mutations that tend to precipitate transformation to AML are gain-of-function mutations that are more amenable to FDA-approved targeted therapies such as FLT3 inhibitors and IDH1/2 inhibitors (80). The gene discussed is FLT3; the disease is acute myeloid leukemia.